DE10337186A1 - Wässrige Wirkstoff-Lösung - Google Patents

Wässrige Wirkstoff-Lösung Download PDF

Info

Publication number
DE10337186A1
DE10337186A1 DE10337186A DE10337186A DE10337186A1 DE 10337186 A1 DE10337186 A1 DE 10337186A1 DE 10337186 A DE10337186 A DE 10337186A DE 10337186 A DE10337186 A DE 10337186A DE 10337186 A1 DE10337186 A1 DE 10337186A1
Authority
DE
Germany
Prior art keywords
solution according
salt
zinc
aqueous pharmaceutical
oxymetazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10337186A
Other languages
German (de)
English (en)
Inventor
Frank Boehme
Bernd Eschenbach
Dagmar Faerber
Claudia Dr. Hey
Barbara Pfaff
Marion Dr. med. Tschaikin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10337186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE10337186A priority Critical patent/DE10337186A1/de
Priority to US10/567,845 priority patent/US20060222718A1/en
Priority to AT04740995T priority patent/ATE357212T1/de
Priority to PL04740995T priority patent/PL1663141T3/pl
Priority to KR1020067002872A priority patent/KR20060065677A/ko
Priority to BRPI0413478-8A priority patent/BRPI0413478A/pt
Priority to EP04740995A priority patent/EP1663141B1/de
Priority to RU2006107446/15A priority patent/RU2343918C2/ru
Priority to AU2004266443A priority patent/AU2004266443A1/en
Priority to JP2006522915A priority patent/JP4750703B2/ja
Priority to MXPA06001596A priority patent/MXPA06001596A/es
Priority to ES04740995T priority patent/ES2282871T3/es
Priority to DE502004003305T priority patent/DE502004003305D1/de
Priority to DK04740995T priority patent/DK1663141T3/da
Priority to PCT/EP2004/007780 priority patent/WO2005018601A1/de
Priority to PT04740995T priority patent/PT1663141E/pt
Priority to CNB2004800227931A priority patent/CN100531733C/zh
Priority to SI200430324T priority patent/SI1663141T1/sl
Priority to CA2535533A priority patent/CA2535533C/en
Publication of DE10337186A1 publication Critical patent/DE10337186A1/de
Priority to ZA200602071A priority patent/ZA200602071B/en
Priority to US11/567,845 priority patent/US7338116B1/en
Priority to CY20071100685T priority patent/CY1107633T1/el
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE10337186A 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung Withdrawn DE10337186A1 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
CA2535533A CA2535533C (en) 2003-08-13 2004-07-14 Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
MXPA06001596A MXPA06001596A (es) 2003-08-13 2004-07-14 Solucion farmaceutica acuosa que comprende oximetazolina y/o xilometazolina.
DE502004003305T DE502004003305D1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
PL04740995T PL1663141T3 (pl) 2003-08-13 2004-07-14 Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę
KR1020067002872A KR20060065677A (ko) 2003-08-13 2004-07-14 옥시메타졸린 및/또는 크실로메타졸린을 포함하는 약제학적수용액
BRPI0413478-8A BRPI0413478A (pt) 2003-08-13 2004-07-14 solução farmacêutica aquosa compreendendo oximetazolina e/ou xilometazolina
EP04740995A EP1663141B1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
RU2006107446/15A RU2343918C2 (ru) 2003-08-13 2004-07-14 Водный фармацевтический раствор, содержащий оксиметазолин и/или ксилометазолин
AU2004266443A AU2004266443A1 (en) 2003-08-13 2004-07-14 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
JP2006522915A JP4750703B2 (ja) 2003-08-13 2004-07-14 オキシメタゾリン及び／又はキシロメタゾリンを含有する医薬水溶液
US10/567,845 US20060222718A1 (en) 2003-08-13 2004-07-14 Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
ES04740995T ES2282871T3 (es) 2003-08-13 2004-07-14 Solucion farmaceutica, acuosa, que contiene oximetazolina y/o xilometazolina.
AT04740995T ATE357212T1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
DK04740995T DK1663141T3 (da) 2003-08-13 2004-07-14 Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin
PCT/EP2004/007780 WO2005018601A1 (de) 2003-08-13 2004-07-14 Wässrige phramateuziche lösung enthaltend oxymetazolin und/oder xylometazolin
PT04740995T PT1663141E (pt) 2003-08-13 2004-07-14 Solução farmacêutica aquosa contendo oximetazolina e/ou xilometazolina
CNB2004800227931A CN100531733C (zh) 2003-08-13 2004-07-14 包含羟甲唑啉和/或赛洛唑啉的水性药物溶液
SI200430324T SI1663141T1 (sl) 2003-08-13 2004-07-14 Vodna farmacevtska raztopina, ki vsebuje oksimetazolin in/ali ksilometazolin
ZA200602071A ZA200602071B (en) 2003-08-13 2006-03-10 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
US11/567,845 US7338116B1 (en) 2003-08-13 2006-12-07 Folding chair
CY20071100685T CY1107633T1 (el) 2003-08-13 2007-05-21 Υδατικο φαρμακευτικο διαλυμα περιεχον οξυμεταζολινη και/ή ξυλομεταζολινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung

Publications (1)

Publication Number Publication Date
DE10337186A1 true DE10337186A1 (de) 2005-03-17

Family

ID=34201503

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10337186A Withdrawn DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
DE502004003305T Expired - Lifetime DE502004003305D1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004003305T Expired - Lifetime DE502004003305D1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin

Country Status (19)

Country Link
US (1) US20060222718A1 (https=)
EP (1) EP1663141B1 (https=)
JP (1) JP4750703B2 (https=)
KR (1) KR20060065677A (https=)
CN (1) CN100531733C (https=)
AT (1) ATE357212T1 (https=)
AU (1) AU2004266443A1 (https=)
BR (1) BRPI0413478A (https=)
CA (1) CA2535533C (https=)
CY (1) CY1107633T1 (https=)
DE (2) DE10337186A1 (https=)
DK (1) DK1663141T3 (https=)
ES (1) ES2282871T3 (https=)
MX (1) MXPA06001596A (https=)
PL (1) PL1663141T3 (https=)
PT (1) PT1663141E (https=)
RU (1) RU2343918C2 (https=)
WO (1) WO2005018601A1 (https=)
ZA (1) ZA200602071B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202012002792U1 (de) 2011-12-30 2013-01-03 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
DE102017117987A1 (de) 2017-07-31 2019-01-31 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE102007052380A1 (de) † 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101576539B (zh) * 2009-06-19 2012-05-23 广东省药品检验所 一种盐酸赛洛唑啉中杂质a的测定方法
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US20170348230A1 (en) 2014-12-24 2017-12-07 Jadran-Galenski Laboratorij D.D A nasal composition containing sea water as stability-improving excipient
BR112018072177A2 (pt) * 2016-05-17 2019-02-12 Proponent Biotech Gmbh composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
CN107362141B (zh) * 2017-08-16 2018-06-05 深圳大佛药业股份有限公司 一种盐酸羟甲唑啉鼻喷雾剂及其制备方法
US20210244710A1 (en) * 2018-07-02 2021-08-12 Kangping Xiao Stable pharmaceutical formulations of oxymetazoline
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
WO2023046590A1 (en) 2021-09-22 2023-03-30 Jadran - Galenski Laboratorij D.D. An improved pharmaceutical composition for nasal use, preparation, and use thereof
CN117982422B (zh) * 2024-04-03 2024-07-26 深圳大佛药业股份有限公司 一种用于治疗鼻炎的喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
CA2311530C (en) * 1998-01-30 2008-06-10 Novartis Consumer Health S.A. Nasal solutions
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
NL1011016C2 (nl) * 1999-01-13 2000-07-14 Dagra Pharma Bv Neusspray op basis van xylometazoline en kamille-extract.
AU765736B2 (en) * 1999-06-22 2003-09-25 Boehringer Ingelheim International Gmbh Stable xylometazoline and oxymetazoline solution
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
RU2212235C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Капли назальные бризолин, обладающие сосудосуживающим, противовоспалительным и противоотечным действием

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202012002792U1 (de) 2011-12-30 2013-01-03 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
WO2013097911A1 (de) 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale applikation mit verbesserter stabilität
DE102012005452A1 (de) 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
EP2818163A1 (de) 2011-12-30 2014-12-31 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
EP4410369A2 (de) 2011-12-30 2024-08-07 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
DE102017117987A1 (de) 2017-07-31 2019-01-31 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
WO2019025040A1 (de) 2017-07-31 2019-02-07 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale applikation

Also Published As

Publication number Publication date
AU2004266443A1 (en) 2005-03-03
JP4750703B2 (ja) 2011-08-17
ATE357212T1 (de) 2007-04-15
RU2006107446A (ru) 2007-09-20
CN100531733C (zh) 2009-08-26
WO2005018601A1 (de) 2005-03-03
DK1663141T3 (da) 2007-07-30
PT1663141E (pt) 2007-06-27
ZA200602071B (en) 2007-05-30
BRPI0413478A (pt) 2006-10-17
EP1663141A1 (de) 2006-06-07
JP2007501817A (ja) 2007-02-01
MXPA06001596A (es) 2006-05-19
RU2343918C2 (ru) 2009-01-20
CA2535533A1 (en) 2005-03-03
KR20060065677A (ko) 2006-06-14
CY1107633T1 (el) 2013-03-13
PL1663141T3 (pl) 2007-07-31
EP1663141B1 (de) 2007-03-21
DE502004003305D1 (de) 2007-05-03
US20060222718A1 (en) 2006-10-05
CN1832726A (zh) 2006-09-13
CA2535533C (en) 2011-10-18
ES2282871T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DE69520492T2 (de) Flüssige arzneizubereitungen enthaltend schilddrüsenhormone
EP0316633B1 (de) Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge
EP1663141B1 (de) Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
DE60114571T2 (de) Formulierungen, enthaltend einen anticholinergen Wirkstoff für die Behandlung der chronisch obstruktiven pulmonalen Erkrankung
AT394947B (de) Verfahren zur herstellung einer fluessigen nasal verabreichbaren calcitoninzusammensetzung
DE602004012718T2 (de) Formulierung für einen dosierinhalator unter verwendung von hydro-fluoro-alkanen als treibstoffe
DE69920201T2 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
EP1255557B1 (de) Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung enthaltend desmopressin
DE69818026T2 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
DE4139017C2 (de) Wäßrige Piroxicam-Lösungen und Verfahren zu ihrer Herstellung
EP2766008B1 (de) Zusammensetzung für die nasale applikation mit verbesserter stabilität
WO2001010408A2 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
DE69300017T2 (de) Wässrige pharmazeutische Zubereitung von Natriumcromoglykat.
WO1994023711A1 (de) Stabile ketamin-lösungen
DE60103284T2 (de) Antifungizide zusammensetzung von ketoconazole zum auftragen
WO2010066437A2 (de) Wässrige zusammensetzung enthaltend dexpanthenol und natriumchlorid
EP0591710A1 (de) Mesna-Injektionslösungen
DE68903937T2 (de) Waessrige elcatonin-loesung enthaltende arzneizubereitung.
DE68912947T2 (de) Ein lösliches ibopamin-salz enthaltende augenarzneizubereitung.
EP0529499A1 (de) Pharmazeutische Zusammensetzungen enthaltend Bradykinin-Antagonisten zur lokalen Anwendung an Nase und Auge
EP3099330B1 (de) Stabile alkoholische lösung von alprostadil
DE69000621T2 (de) Pentamidinloesungen.
EP1807112B1 (de) Stabile wässrige formulierungen eines platin derivats
DE3302949C2 (https=)
DE102004031538A1 (de) Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee